Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001032060 | SCV001195367 | likely pathogenic | Hereditary breast ovarian cancer syndrome | 2019-07-22 | criteria provided, single submitter | clinical testing | This variant is an in-frame deletion of the genomic region encompassing exons 7-11 of the BRCA1 gene. It preserves the integrity of the reading frame. This variant has not been reported in the literature in individuals with BRCA1-related conditions. This variant deletes almost 67% of the BRCA1 protein and it is expected to disrupt several nuclear localization signals and DNA binding and colied-coil domains, which mediate interactions with RAD51, RAD50 and PALB2 (PMID: 25652403, 22737296). While functional studies have not been performed to directly test the effect of this variant on BRCA1 protein function, this suggests that disruption of this region of the protein is causative of disease. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |